Differentiated and dose-related cardiovascular effects of a dual endothelin receptor antagonist in endotoxin shock

Critical Care Medicine

Volumn 32, Issue 5, 2004, Pages 1192-1199

  Konrad, David ^a   Oldner, Anders ^a   Rossi, Patrik ^a   Wanecek, Michael ^a   Rudehill, Anders ^a   Weitzberg, Eddie ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cardiac; Echocardiography; Sepsis; Tezosentan; Troponin

Indexed keywords

DEXTRAN; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTOXIN; MACRODEX 60; TEZOSENTAN; TROPONIN I;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTERY CATHETERIZATION; ARTICLE; CARDIOVASCULAR SYSTEM; CLINICAL RESEARCH; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY SINUS; DETERIORATION; DOMESTICATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MEGADOSE; DRUG RESEARCH; DRUG SCREENING; ECHOCARDIOGRAPHY; ENDOTOXEMIA; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FUNCTION; HEART RATE; HEART STROKE VOLUME; HEMODYNAMIC MONITORING; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MEDICAL ASSESSMENT; METABOLIC ACIDOSIS; NONHUMAN; PERFORMANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY ARTERY OCCLUSION; PULMONARY HYPERTENSION; RESUSCITATION; SEPTIC SHOCK; SWINE; SYSTEMIC VASCULAR RESISTANCE; UNIVERSITY;

ANIMALS; CARDIOVASCULAR SYSTEM; CORONARY CIRCULATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG MONITORING; ECHOCARDIOGRAPHY; ENDOTHELIN-1; ENDOTHELIN-2; HEART CATHETERIZATION; INFUSIONS, INTRAVENOUS; PYRIDINES; RECEPTORS, ENDOTHELIN; RESUSCITATION; SHOCK, SEPTIC; STROKE VOLUME; SWINE; TETRAZOLES; TROPONIN I; VASCULAR RESISTANCE; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 2442557223     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000126262.23422.F0     Document Type: Article

References (54)

1. Kumar A, Krieget A, Symeoneides S, et al: Myocardial dysfunction in septic shock: Part II. Role of cytokines and nitric oxide. J Cardiothorac Vasc Anesth 2001; 15:485-511
2. Channick RN, Simonneau G, Sitbon O, et al: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet 2001; 358:1119-1123
3. Benigni A, Zoja C, Corna D, et al: A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993; 44:440-444
4. Clozel M, Watanabe H: BQ-123, a peptidic endothelin ETA receptor antagonist, prevents the early cerebral vasospasm following subarachnoid hemorrhage after intracisternal but not intravenous injection. Life Sci 1993; 52:825-834
5. Modesti PA, Vanni S, Paniccia R, et al: Endothelin receptors in adult human and swine isolated ventricular cardiomyocytes. Biochem Pharmacol 1999; 58:369-374
6. Seo B, Oemar BS, Siebenmann R, et al: Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation 1994; 89:1203-1208
7. Tomoda H: Plasma endothelin-1 in acute myocardial infarction with heart failure. Am Heart J 1993; 125:667-672
8. Qiu S, Theroux P, Marcil M, et al: Plasma endothelin-1 levels in stable and unstable angina. Cardiology 1993; 82:12-19
9. Wei CM, Lerman A, Rodeheffer RJ, et al: Endothelin in human congestive heart failure. Circulation 1994; 89:1580-1586
10. Sutsch G, Kiowski W, Yan XW, et al: Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998; 98:2262-2268
11. Weitzberg E, Lundberg JM, Rudehill A: Elevated plasma levels of endothelin in patients with sepsis syndrome. Circ Shock 1991; 33:222-227
12. Takakuwa T, Endo S, Nakae H, et al: Plasma levels of TNF-alpha, endothelin-1 and thrombomodulin in patients with sepsis. Res Commun Chem Pathol Pharmacol 1994; 84:261-269
13. Brauner JS, Rohde LE, Clausell N: Circulating endothelin-1 and tumor necrosis factor-alpha: Early predictors of mortality in patients with septic shock. Intensive Care Med 2000; 26:305-313
14. Wanecek M, Oldner A, Rudehill A, et al: Cardiopulmonary dysfunction during porcine endotoxin shock is effectively counteracted by the endothelin receptor antagonist bosentan. Shock 1997; 7:364-370
15. Oldner A, Wanecek M, Goiny M, et al: The endothelin receptor antagonist bosentan restores gut oxygen delivery and reverses intestinal mucosal acidosis in porcine endotoxin shock. Gut 1998; 42:696-702
16. Clozel M, Ramuz H, Clozel JP, et al: Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther 1999; 290:840-846
17. Torre-Amione G, Young JB, Durand J, et al: Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation 2001; 103:973-980
18. Schalcher C, Cotter G, Reisin L, et al: The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure. Am Heart J 2001; 142:340-349
19. Hemsen A: Biochemical and functional characterization of endothelin peptides with special reference to vascular effects. Acta Physiol Scand 1991; 602(Suppl.)1-61
20. Kumar A, Haery C, Parrillo JE: Myocardial dysfunction in septic shock. Part I. Clinical manifestation of cardiovascular dysfunction. J Cardiothorac Vasc Anesth 2001; 15:364-376
21. Goldberg AT, Bond BR, Mukherjee R, et al: Endothelin receptor pathway in human left ventricular myocytes: Relation to contractility. Ann Thorac Surg. 2000; 69:711-716
22. Beyer ME, Nerz S, Kazmaier S, et al: Effect of endothelin-1 and its combination with adenosine on myocardial contractility and myocardial energy metabolism in vivo. J Mol Cell Cardiol 1995; 27:1989-1997
23. Cirino M, Martin E, Yano M, et al: Cardiovascular and renal actions of the endothelin(B) receptor in pigs. J Cardiovasc Pharmacol 1997; 29:704-712
24. Beyer ME, Slesak G, Brehm BR, et al: Hemodynamic and inotropic effects of the endothelin A antagonist BQ-610 in vivo. J Cardiovasc Pharmacol 1998; 31(Suppl 1):S258-261
25. Szabo G, Bahrle S, Fazekas L, et al: The role of endothelin-B receptors in myocardial and endothelial reperfusion injury after heart transplantation. Thorac Cardiovasc Surg 2001; 49:167-171
26. Pearl JM, Nelson DP, Wagner CJ, et al: Endothelin receptor blockade reduces ventricular dysfunction and injury after reoxygenation. Ann Thorac Surg 2001; 72:565-570
27. Thomas PB, Liu EC, Webb ML, et al: Exogenous effects and endogenous production of endothelin in cardiac myocytes: Potential significance in heart failure. Am J Physiol 1996; 271:H2629-2637
28. Szabo G, Bahrle S, Fazekas L, et al: Endothelin-A receptor antagonist BQ123 protects against myocardial and endothelial reperfusion injury. Thorac Cardiovasc Surg 1998; 46:232-236
29. Kaszaki J, Wolfard A, Boros M, et al: Effects of antiendothelin treatment on the early hemodynamic changes in hyperdynamic endotoxemia. Acta Chir Hung 1997; 36:152-153
30. Wanecek M, Weitzberg E, Alving K, et al: Effects of the endothelin receptor antagonist bosentan on cardiac performance during porcine endotoxin shock. Acta Anaesthesiol Scand 2001; 45:1262-1270
31. Chin A, Radhakrishnan J, Fornell L, et al: Effects of tezosentan, a dual endothelin receptor antagonist, on the cardiovascular and renal systems of neonatal piglets during endotoxic shock. J Pediatr Surg 2002; 37:482-487
32. Thys DM, Hillel Z, Goldman ME, et al: A comparison of hemodynamic indices derived by invasive monitoring and two-dimensional echocardiography. Anesthesiology 1987; 67:630-634
33. Ognibene FP, Parker MM, Natanson C, et al: Depressed left ventricular performance. Response to volume infusion in patients with sepsis and septic shock. Chest 1988; 93:903-910
34. Werner HA, Herbertson MJ, Walley KR: Amrinone increases ventricular contractility and diastolic compliance in endotoxemia. Am J Respir Crit Care Med 1995; 152:496-503
35. Schneider AJ, Teule GJ, Groeneveld AB, et al: Biventricular performance during volume loading in patients with early septic shock, with emphasis on the right ventricle: A combined hemodynamic and radionuclide study. Am Heart J 1988; 116:103-112
36. Parker MM, Shelhamer JH, Bacharach SL, et al: Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 1984; 100:483-490
37. Yamamoto K, Masuyama T, Sakata Y, et al: Prevention of diastolic heart failure by endothelin type A receptor antagonist through inhibition of ventricular structural remodeling in hypertensive heart. J Hypertens 2002; 20:753-761
38. Sibbald WJ, Paterson NA, Holliday RL, et al: Pulmonary hypertension in sepsis: Measurement by the pulmonary arterial diastolic-pulmonary wedge pressure gradient and the influence of passive and active factors. Chest 1978; 73:583-591
39. Vincent JL, Reuse C, Frank N, et al: Right ventricular dysfunction in septic shock: Assessment by measurements of right ventricular ejection fraction using the thermodilution technique. Acta Anaesthesiol Scand 1989; 33:34-38
40. Lee K, van der Zee H, Dziuban SW Jr, et al: Left ventricular function during chronic endotoxemia in swine. Am J Physiol 1988; 254: H324-330
41. Cunnion RE, Schaer GL, Parker MM, et al: The coronary circulation in human septic shock. Circulation 1986; 73:637-644
42. Dhainaut JF, Huyghebaert MF, Monsallier JF, et al: Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock. Circulation 1987; 75:533-541
43. Ammann P, Fehr T, Minder EI, et al: Elevation of troponin I in sepsis and septic shock. Intensive Care Med 2001; 27:965-969
44. ver Elst KM, Spapen HD, Nguyen DN, et al: Cardiac troponins I and T are biological markers of left ventricular dysfunction in septic shock. Clin Chem 2000; 46:650-657
45. Fernandes CJ Jr, Akamine N, Knobel E: Cardiac troponin: A new serum marker of myocardial injury in sepsis. Intensive Care Med 1999; 25:1165-1168
46. Maxwell L, Pratt K, Gavin J: Endothelin-3-induced microvascular incompetence and mitochondrial damage in rat myocardium. Clin Exp Pharmacol Physiol 1992; 19:683-688
47. Maxwell L, Harrison WR, Gavin JB: Endothelin antagonists diminish postischemic microvascular incompetence and necrosis in the heart. Microvasc Res 2000; 59:204-212
48. Galiuto L, DeMaria AN, del Balzo U, et al: Ischemia-reperfusion injury at the microvascular level: Treatment by endothelin A-selective antagonist and evaluation by myocardial contrast echocardiography. Circulation 2000; 102:3111-3116
49. Tschaikowsky K, Sagner S, Lehnert N, et al: Endothelin in septic patients: Effects on cardiovascular and renal function and its relationship to proinflammatory cytokines. Crit Care Med 2000; 28:1854-1860
50. Dupuis J, Goresky CA, Fournier A: Pulmonary clearance of circulating endothelin-1 in dogs in vivo: Exclusive role of ETB receptors. J Appl Physiol 1996; 81:1510-1515
51. Dingemanse J, Clozel M, van Giersbergen PL: Entry-into-humans study with tezosentan, an intravenous dual endothelin receptor antagonist. J Cardiovasc Pharmacol 2002; 39:795-802
52. Oldner A, Wanecek M, Weitzberg E, et al: Differentiated effects on splanchnic homeostasis by selective and non-selective endothelin receptor antagonism in porcine endotoxaemia. Br J Pharmacol 1999; 127:1793-1804
53. Wanecek M, Oldner A, Rudehill A, et al: Endothelin(A)-receptor antagonism attenuates pulmonary hypertension in porcine endotoxin shock. Eur Respir J 1999; 13:145-151
54. Kaluski E, Kobrin I, Zimlichman R, et al: RITZ-5: Randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: A prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol 2003; 41:204-210